A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 165 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
Actual Study Start Date: July 13, 2016
Actual Primary Completion Date: January 21, 2021
Actual Study Completion Date: January 21, 2021
Arms:
- Experimental: Galcanezumab
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 165 |
| Actual Study start date | 13 July 2016 |
| Actual primary completion date | 21 January 2021 |